Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Status:
Completed
Trial end date:
2018-09-11
Target enrollment:
Participant gender:
Summary
This study is being carried out to determine the effect of dapagliflozin on cardiovacular
outcomes when added to current background therapy in patients with type 2 diabetes with
either established cardiovacular disease or cardiovascular risk factors.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Bristol-Myers Squibb Hadassah Medical Organization The TIMI Study Group